Prophylaxis with anti-activated factor XII for hereditary angioedema

Lancet. 2022 Mar 5;399(10328):889-890. doi: 10.1016/S0140-6736(21)02436-3. Epub 2022 Feb 24.

Authors

Lauré M Fijen¹, Marcel Levi²

Affiliations

¹ Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, Netherlands. Electronic address: l.m.fijen@amsterdamumc.nl.
² Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam UMC, University of Amsterdam, 1105 AZ Amsterdam, Netherlands.

PMID: 35219374
DOI: 10.1016/S0140-6736(21)02436-3

No abstract available

MeSH terms

Angioedemas, Hereditary* / drug therapy
Angioedemas, Hereditary* / prevention & control
Complement C1 Inhibitor Protein / therapeutic use
Factor XIIa / therapeutic use
Humans

Substances

Complement C1 Inhibitor Protein
Factor XIIa